Samsung Biologics Surpasses 1 Trillion Won in Operating Profit in Just Half a Year (Update)
Q2 Sales Reach 1.32 Trillion Won, Operating Profit Hits 586.4 Billion Won
Up 30% and 23% Year-on-Year, Respectively
Samsung BioLogics posted outstanding results, surpassing 1 trillion won in operating profit in just half a year.
On July 23, Samsung BioLogics announced via a disclosure that it recorded sales of 1.3209 trillion won and operating profit of 586.4 billion won in the second quarter. Sales increased by 306.7 billion won (30%) and operating profit by 109.2 billion won (23%) compared to the same period last year. The company continued its solid growth, driven by the full operation of plants 1 through 4 and favorable exchange rates. As a result, operating profit in the first half of this year amounted to 1.1672 trillion won, representing a 28.6% increase from 907.4 billion won in the same period last year. This is the first time since its founding that the company has exceeded 1 trillion won in operating profit within half a year.
A panoramic view of Samsung BioLogics Plant 4 in Yeonsu-gu, Incheon. Samsung BioLogics
View original imageDespite the fact that costs related to Plant 5 and the U.S. Rockville production facility were reflected in advance ahead of significant sales recognition, the operating margin remained in the 40% range. Samsung BioLogics expects to achieve the upper end of its annual sales growth guidance this year.
As of the end of the second quarter of 2026, Samsung BioLogics' assets amounted to 12.6526 trillion won, equity amounted to 8.3619 trillion won, and liabilities were 4.2907 trillion won. The company maintained a stable financial structure, with a debt ratio of 51.3% and a borrowing ratio of 11.5%.
Samsung BioLogics continues to secure orders in all areas of contract manufacturing (CMO) and contract development (CDO). Since its founding, cumulative orders have reached 115 for CMO (contract manufacturing) and 176 for CDO (contract development), with a total cumulative order value of 21.7 billion dollars (approximately 32.0943 trillion won).
In terms of global presence, the company plans to open a European sales office in the Netherlands within the third quarter to accelerate its push into global markets. Following the opening of sales offices in New Jersey, U.S. in 2023 and Tokyo, Japan last year, the expansion to Amsterdam, Netherlands this year will provide business hubs in what are considered the three major global biopharmaceutical markets—the U.S., Europe, and Japan—as well as the Asia-Pacific (APAC) region. Based on this, Samsung BioLogics aims to strengthen its order competitiveness and achieve a super-gap in competitiveness through global network expansion.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Regarding its portfolio, the company is steadily broadening its business scope, including the decision to acquire Polypeptide Group, a global peptide CDMO company. In addition to its core antibody drug business, Samsung BioLogics has secured capabilities in developing and manufacturing various new modalities such as messenger RNA (mRNA) and antibody-drug conjugates (ADC). It has also secured land for a third Bio Campus to construct high-value-added new modality production facilities.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.